These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15358979)

  • 1. Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.
    Moresco RM; Cavallaro R; Messa C; Bravi D; Gobbo C; Galli L; Lucignani G; Colombo C; Rizzo G; Velonà I; Smeraldi E; Fazio F
    J Psychopharmacol; 2004 Sep; 18(3):355-65. PubMed ID: 15358979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
    Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET.
    Nordström AL; Farde L; Halldin C
    Psychopharmacology (Berl); 1993; 110(3):365-7. PubMed ID: 7831432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
    Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
    Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.
    Nordström AL; Farde L; Nyberg S; Karlsson P; Halldin C; Sedvall G
    Am J Psychiatry; 1995 Oct; 152(10):1444-9. PubMed ID: 7573582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
    Kapur S
    Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.
    Farde L; Nyberg S; Oxenstierna G; Nakashima Y; Halldin C; Ericsson B
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):19S-23S. PubMed ID: 7537284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.
    Nordström AL; Nyberg S; Olsson H; Farde L
    Arch Gen Psychiatry; 1998 Mar; 55(3):283-4. PubMed ID: 9510228
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
    Markianos M; Hatzimanolis J; Lykouras L; Christodoulou GN
    Schizophr Res; 2002 Jul; 56(1-2):11-7. PubMed ID: 12084414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
    Nyberg S; Farde L; Halldin C
    Neuropsychopharmacology; 1997 Jan; 16(1):1-7. PubMed ID: 8981383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol.
    Karbe H; Wienhard K; Hamacher K; Huber M; Herholz K; Coenen HH; Stöcklin G; Lövenich A; Heiss WD
    J Neural Transm Gen Sect; 1991; 86(3):163-73. PubMed ID: 1837996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.